Literature DB >> 25504279

Transfusion support issues in hematopoietic stem cell transplantation.

Claudia S Cohn1.   

Abstract

BACKGROUND: Patients receiving hematopoietic stem cell transplantation require extensive transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable complications may arise when the transplanted stem cells are incompatible with the native ABO type of the patient. Immediate and delayed hemolysis is often seen.
METHODS: A literature review was performed and the results from peer-reviewed papers that contained reproducible findings were integrated.
RESULTS: A strong body of clinical evidence has developed around the common complications experienced with ABO-incompatible hematopoietic stem cell transplantation. These complications are discussed and the underlying pathophysiology is explained. General treatment options and guidelines are enumerated.
CONCLUSIONS: ABO-incompatible hematopoietic stem cell transplantations are frequently performed. Immune-related hemolysis is a commonly encountered complication; therefore, health care professionals must recognize the signs of immune-mediated hemolysis and understand the various etiologies that may drive the process.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25504279     DOI: 10.1177/107327481502200108

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  2 in total

Review 1.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

2.  Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.

Authors:  Linda M Griffith; Mark VanRaden; A John Barrett; Richard W Childs; Daniel H Fowler; Elizabeth M Kang; John F Tisdale; Harvey G Klein; David F Stroncek
Journal:  Transfusion       Date:  2018-10-26       Impact factor: 3.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.